Study Summary
This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy.. Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.
Want to learn more about this trial?
Request More InfoInterventions
MT027 cells suspensionDRUG
MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijing | China |